Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PET Imaging Agent Vizamyl Filed for Additional Use for AD Modifying Drug
April 13, 2023
- Alexion Japan Recalling Ultomiris IV 300 mg/3 mL
April 13, 2023
- Japan Lacks Talent, Ecosystem to Incubate Drug Seeds: Chugai Chair
April 13, 2023
- Astellas, Kyoto University’s CiRA Extend iPS Cell Pact
April 13, 2023
- Astellas Incurs 58 Billion Yen Impairment Loss on Sluggish Evrenzo, Other Factors
April 12, 2023
- Sumitomo’s SaMD for Depression Gets Priority Review; Clinical Trial Launch Eyed within 3 Years
April 12, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Shionogi Seeks EUA for Xocova in Taiwan
April 12, 2023
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Wakamoto to Halt Shipments of MaQaid on Quality Issues
April 11, 2023
- Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
April 11, 2023
- MSD Rolls Out 15-Valent Pneumococcal Vaccine Vaxneuvance in Japan
April 11, 2023
- Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
April 11, 2023
- Ono/BMS Settles PD-1/PD-L1 Patent Row with Dana-Farber
April 10, 2023
- Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
April 10, 2023
- Sanofi Discontinues Sales of Allegra Dry Syrup in Japan
April 10, 2023
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
- Japan Ethical Drug Sales Up 0.6% in February: Crecon
April 10, 2023
- Lenvima/Keytruda Combo Fails in 1st-Line Melanoma Study
April 10, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…